SCHEMBL3979322

SCHEMBL3979322

COC(=O)[C@@H]1C[C@@H](NCc2ccc(F)cc2F)CN1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.41
ACHE P22303 2/20 0.41
BACE1 P56817 2/20 0.41
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
PTPN1 P18031 1/20 0.38
APP P05067 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
SLC6A2 P23975 1/20 0.38
HRH2 P25021 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2819384 1.00 BCHE (0.41) BCHEACHEBACE1CCNT1CDK9
SCHEMBL14544426 0.80 MMP2 (0.44) NR1H2NR1H3PTPN1CYP3A4CYP1A2
SCHEMBL14521947 0.80 MMP2 (0.44) NR1H2NR1H3PTPN1CYP3A4CYP1A2
SCHEMBL24538202 0.79 MMP2 (0.47) ACHENR1H2NR1H3PTPN1MMP2
SCHEMBL12166250 0.79 MMP2 (0.47) ACHENR1H2NR1H3PTPN1MMP2
SCHEMBL2824741 0.79 MMP2 (0.47) ACHENR1H2NR1H3PTPN1MMP2
SCHEMBL13841901 0.79 MMP2 (0.47) ACHENR1H2NR1H3PTPN1MMP2
SCHEMBL21659108 0.78 NPFFR1 (0.45) NR1H2NR1H3ALDH1A1CYP3A4MMP2
SCHEMBL13060193 0.77 GPR119 (0.56) BCHEACHEBACE1GPR119ALDH1A1
SCHEMBL29673206 0.77 GPR119 (0.56) BCHEACHEBACE1GPR119ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 BCHE 2225/4885ACHE 548/4885BACE1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.